SubHero Banner

Keytruda® (pembrolizumab), Tecentriq® (atezolizumab) – Safety communication

May 18, 2018 - The FDA announced that decreased survival is associated with the use of Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).

Download PDF